Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07539155 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2026 to Jun 26, 2026
    v3
  2. Start date: Apr 2026 to Aug 2026
    • Primary and study completion pushed from Mar 2028 to Aug 2028
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
Trial Details
NCT Number NCT07539155
Lead Sponsor University of Arkansas
Conditions
(from sponsor)		 Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov